Forwardlooking statements include statements concerning the potential of our product candidates including the reproducibility and durability of any favorable results initially seen in our first patient dosed in the REVEAL trial and including our preclinical product candidates to positively impact quality of life and alter the course of disease in the patients we seek to treat our research development and regulatory plans for our product candidates the potential for these product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies and whether if approved these product candidates will be successfully distributed and marketed the potential market opportunity for these product candidates our corporate growth plans statements associated with the timing size and completion of the Private Placement the forecast of our cash runway and the Companys expectations regarding funding operating and working capital expenditures